Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts
26 sept. 2024 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in the multiple-ascending dose (MAD)...
With 13.16% CAGR, Global Cloud Based Drug Discovery Platform Market Size to Hit USD 6348.36 Million by 2030 - Exclusive Report by Facts & Factors
30 sept. 2023 13h53 HE
|
Zion Market Research
NEW YORK, United States, Sept. 30, 2023 (GLOBE NEWSWIRE) -- Facts and Factors has published a new research report titled “Cloud Based Drug Discovery Platform Market Size, Share, Growth Analysis...
Vyant Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
16 nov. 2022 16h43 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article
06 sept. 2022 09h00 HE
|
Gb Sciences
LAS VEGAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, describes their progress towards...
Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
11 août 2022 08h00 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Gb Sciences is Leading Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™
19 juil. 2022 09h31 HE
|
Gb Sciences
LAS VEGAS, July 19, 2022 (GLOBE NEWSWIRE) -- Gb Sciences is a plant-inspired, biopharmaceutical research and drug development company that began building its proprietary digital research and...
Gb Sciences Leads Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™
18 juil. 2022 09h02 HE
|
Gb Sciences
LAS VEGAS, July 18, 2022 (GLOBE NEWSWIRE) -- Gb Sciences is a plant-inspired, biopharmaceutical research and drug development company that began building its proprietary digital research and...
TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit
12 mai 2022 09h00 HE
|
Gb Sciences
LAS VEGAS, May 12, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and...
UPDATE: Gb Sciences Issues Shareholder Letter
16 mars 2022 15h01 HE
|
Gb Sciences
LAS VEGAS, March 16, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, today issued a letter to...
Gb Sciences Issues Summary Shareholder Letter
15 mars 2022 07h00 HE
|
Gb Sciences
LAS VEGAS, March 15, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, today issued a letter to...